Tianjin, 6 February 2025 - CanSino Biologics Inc (“CanSinoBIO” or “the Company”) is pleased to announce that Menhycia^®[Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), MCV4] has been granted Halal Decree by the Assessment Institute for Foods, Drugs and Cosmetics of Majelis Ulama Indonesia (LPPOM MUI), further reinforcing our commitment to providing innovative, high-quality, affordable and culturally respectful solutions.

Menhycia^® is a China first-in-class and first NDA approved MCV4 vaccine. Since it launched and commercialized in China in 2021, Menhycia^® has demonstrated safety and efficacy, providing protection to millions of children. The widespread use in China highlights its reliability and impact in preventing meningococcal disease. Currently, Menhycia^® is undergoing clinical trials in Indonesia to expand its application for individuals aged 3 months to 3 years and 18 to 55 years. This initiative is aiming to provide broad protection across a wide age range.

This is the second vaccine of CanSinoBIO obtained Halal Decree certification, ensuring that our vaccine meets the highest standards of quality and compliance with Islamic dietary laws. This certification will enable us to better serve the Indonesian population and other Muslim-majority regions, addressing critical public health needs with respect to cultural and religious considerations.

This achievement highlights CanSinoBIO's unwavering commitment to advancing global health through innovative vaccine development, alongside efforts to ensure that vaccines are accessible to a wide range of communities worldwide.